Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes
Key Findings:
Dapagliflozin, a medication for type 2 diabetes, was found to reduce plasma IL-1B and increase ketone levels, indicating a potential anti-inflammatory effect. The drug also showed no change in PBMC mitochondrial respiration, suggesting a positive impact on inflammation.
Practical Solutions and Value:
This clinical trial provides evidence of the potential benefits of dapagliflozin in reducing systemic inflammation in patients with type 2 diabetes, which could have implications for improving cardiovascular outcomes. The findings highlight the practical value of this medication in managing inflammation in diabetic patients without known heart failure.
Registration and References:
This clinical trial is registered under NCT03782259 and the results were published in Cardiovasc Diabetol. 2024 Jun 7;23(1):197. doi: 10.1186/s12933-024-02294-z.
AI-Driven Platform for Clinical Trials and Medical Practice
Streamlining Operations:
DocSym, our AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
Mobile Apps for Healthcare Management:
Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally, thus streamlining operations in today’s healthcare environment.
Enhancing Workflows with AI:
By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines and enhancing efficiency. Learn more about how we can help at aidevmd.com.
